We are a vertically integrated, clinical stage gene therapy company with four ongoing clinical programs and a broad pipeline of preclinical and research programs. We have core capabilities in viral vector design and optimization and gene therapy manufacturing, as well as a potentially transformative gene regulation technology. Led by an experienced management team, we have taken a portfolio approach by licensing, acquiring and developing technologies that give us depth across both product candidates and indications. Though initially focusing on the eye, salivary gland and central nervous system, we intend to expand our focus in the future to develop additional gene therapy treatments for patients suffering from a range of serious diseases. Source
No articles found.
Cue Biopharma is an innovative clinical stage immunotherapy company developing a n...
Cue Biopharma is an innovative clinical stage i...
CytoSorbents Corporation (NASDAQ: CTSO) is a New Jersey-based, critical care immun...
CytoSorbents Corporation (NASDAQ: CTSO) is a Ne...
WayBetter helps motivate people to adopt healthy behaviors through a combination o...
WayBetter helps motivate people to adopt health...
Genobank is the first privacy-preserving personal DNA Kit that guarantees consumer...
Genobank is the first privacy-preserving person...
CytoDyn is a publicly traded late stage biotechnology company developing innovativ...
CytoDyn is a publicly traded late stage biotech...
IRADIMED CORPORATION is a leader in the development of innovative magnetic resonan...
IRADIMED CORPORATION is a leader in the develop...
Axovant is accelerating the development of innovative gene therapy products that a...
Axovant is accelerating the development of inno...
Join the National Investor Network and get the latest information with your interests in mind.